Literature DB >> 2145579

Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex.

A Karpas1, I K Hewlett, F Hill, J Gray, N Byron, D Gilgen, V Bally, J K Oates, B Gazzard, J E Epstein.   

Abstract

We tried to assess the long-term safety and potential efficacy of passive immunization in AIDS-related-complex (ARC) and AIDS patients. We also wanted to establish whether hyperimmune plasma from healthy human immunodeficiency virus 1 (HIV-1)-infected individuals clears the cell-free virus from circulation. Using the polymerase chain reaction (PCR), we were able to provide conclusive evidence that hyperimmune plasma is effective and maintains long-term neutralization of viremia. Using the cell test, we found that in most patients the total antibody level was maintained; in one of the ARC patients, it actually increased 8-fold and has remained at that level for nearly 2 years. The CD4+ cell count decreased in the AIDS patients but was stable in the ARC patient. Clinically, there was an initial improvement in all patients, but five of six of the advanced/terminal AIDS patients had died by month 17. Our studies suggest that passive immunization may be safe in ARC and AIDS patients. It reduces HIV-1 viremia to levels undetectable even by PCR. To advanced/terminal patients, the benefit is of limited duration, while to ARC patients it may be long-term. Therefore, passive immunization should start early in the disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145579      PMCID: PMC54798          DOI: 10.1073/pnas.87.19.7613

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Passive immunization in ARC and AIDS.

Authors:  A Karpas; J Gray; N Byron; D Gilgen; V Bally; J K Oates; B Gazzard
Journal:  Biotherapy       Date:  1990

2.  Lytic infection by British AIDS virus and development of rapid cell test for antiviral antibodies.

Authors:  A Karpas; W Gillson; P C Bevan; J K Oates
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

3.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

4.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

5.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

6.  Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.

Authors:  A Ranki; S H Weiss; S L Valle; J Antonen; K J Krohn
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

7.  Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.

Authors:  S L Hu; P N Fultz; H M McClure; J W Eichberg; E K Thomas; J Zarling; M C Singhal; S G Kosowski; R B Swenson; D C Anderson
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

8.  Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.

Authors:  A M Prince; B Horowitz; L Baker; R W Shulman; H Ralph; J Valinsky; A Cundell; B Brotman; W Boehle; F Rey
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

9.  Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.

Authors:  P W Berman; J E Groopman; T Gregory; P R Clapham; R A Weiss; R Ferriani; L Riddle; C Shimasaki; C Lucas; L A Lasky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

View more
  18 in total

1.  Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS?

Authors:  D R Bainbridge; M W Lowdell; I M Hannet; K W Strauss; A Karpas
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-07-29       Impact factor: 6.237

Review 2.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 3.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

Review 4.  Molecular biology made easy. The polymerase chain reaction.

Authors:  A M Clarke; N P Mapstone; P Quirke
Journal:  Histochem J       Date:  1992-12

5.  Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.

Authors:  M Holodniy; D A Katzenstein; D M Israelski; T C Merigan
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

Review 6.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

Review 7.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

8.  Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.

Authors:  K J Hasenkrug; D M Brooks; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

Review 9.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

10.  Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  D C Montefiori; B S Graham; S Kliks; P F Wright
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.